NZ583851A - Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases - Google Patents

Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases

Info

Publication number
NZ583851A
NZ583851A NZ583851A NZ58385108A NZ583851A NZ 583851 A NZ583851 A NZ 583851A NZ 583851 A NZ583851 A NZ 583851A NZ 58385108 A NZ58385108 A NZ 58385108A NZ 583851 A NZ583851 A NZ 583851A
Authority
NZ
New Zealand
Prior art keywords
cartilage
cells
slit3
pharmaceutical composition
repellent
Prior art date
Application number
NZ583851A
Other languages
English (en)
Inventor
Anja Bosserhoff
Thomas Schubert
Elisabeth Hustert
Original Assignee
Formycon Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07018131A external-priority patent/EP2036921A1/en
Application filed by Formycon Gmbh filed Critical Formycon Gmbh
Publication of NZ583851A publication Critical patent/NZ583851A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ583851A 2007-09-14 2008-09-12 Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases NZ583851A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07018131A EP2036921A1 (en) 2007-09-14 2007-09-14 Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP08006810 2008-04-03
PCT/EP2008/007579 WO2009033715A2 (en) 2007-09-14 2008-09-12 Neuroendocrine factors for treatment of degenerative diseases

Publications (1)

Publication Number Publication Date
NZ583851A true NZ583851A (en) 2012-06-29

Family

ID=40452588

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ583851A NZ583851A (en) 2007-09-14 2008-09-12 Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases

Country Status (13)

Country Link
US (1) US20110002972A1 (OSRAM)
EP (1) EP2212344B1 (OSRAM)
JP (1) JP2010539123A (OSRAM)
KR (1) KR20100075493A (OSRAM)
CN (1) CN101821283A (OSRAM)
AU (1) AU2008297889A1 (OSRAM)
BR (1) BRPI0816784A8 (OSRAM)
CA (1) CA2699411A1 (OSRAM)
MX (1) MX2010002716A (OSRAM)
NZ (1) NZ583851A (OSRAM)
RU (1) RU2496790C2 (OSRAM)
WO (1) WO2009033715A2 (OSRAM)
ZA (1) ZA201001644B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1400024B1 (it) * 2010-05-21 2013-05-17 Uni Politecnica Delle Marche Uso farmaceutico di semaforine.
CN103703021A (zh) * 2010-12-23 2014-04-02 赛诺菲 用于治疗肝癌的Robo1-Fc融合蛋白
KR101786862B1 (ko) * 2011-07-04 2017-10-18 메소블라스트, 아이엔씨. 류마티즘성 질환을 치료 또는 예방하는 방법
US9802994B2 (en) 2012-06-15 2017-10-31 The Asan Foundation Composition for preventing or treating fracture or osteoporosis using slit-robo system
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119445A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119447A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
WO2015072527A1 (ja) * 2013-11-13 2015-05-21 国立大学法人大阪大学 ネトリン１含有破骨細胞形成抑制剤
ES2989362T3 (es) 2014-03-14 2024-11-26 Univ New York State Res Found Regulación neurogénica del crecimiento óseo y degradación ósea
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US20200397860A1 (en) * 2018-02-14 2020-12-24 Cornell University Slit and bone growth modulation
US20220125879A1 (en) * 2019-02-27 2022-04-28 Daewoong Pharmaceutical Co., Ltd. Albumin-bound composition including lrrd2 of slit3 protein for prevention or treatment of bone-related diseases
KR20220079857A (ko) * 2019-09-13 2022-06-14 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 Aav-상용성 라미닌-링커 중합 단백질
CN110721308B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种用于治疗骨关节炎的药物复方制剂及其制备方法
CN110841057B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎巴布膏剂中的应用
CN110711244B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
CN110684805B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
CN110772632B (zh) * 2019-11-19 2023-08-11 四川大学华西医院 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
CN110694051B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用
US20240277861A1 (en) * 2021-07-26 2024-08-22 Purotech Bio, Inc. Anti-hepatitis b virus agent targeting host factor lipg

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
JPH1116490A (ja) * 1997-06-26 1999-01-22 Kyocera Corp プラズマディスプレイパネル用隔壁の製造方法及びプラズマディスプレイパネル用基板
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1203999A (en) * 1997-10-31 1999-05-24 Osiris Therapeutics, Inc. Human slit polypeptide and polynucleotides encoding same
JPH11164690A (ja) * 1997-12-05 1999-06-22 Asahi Chem Ind Co Ltd 脊椎動物スリット蛋白質
US6924355B2 (en) * 1998-09-01 2005-08-02 Genentech, Inc. PRO1343 polypeptides
JP2002538823A (ja) * 1999-03-17 2002-11-19 ワシントン・ユニバーシティ 脊椎動物のｓｌｉｔＤＮＡ配列、タンパク質およびその使用
AU2001278655A1 (en) * 2000-07-18 2002-01-30 Compugen Ltd. Novel nucleic acid and amino acid sequences
CA2416732C (en) * 2000-08-02 2016-02-09 Brad St. Croix Endothelial cell expression patterns
JP2004523210A (ja) * 2000-08-10 2004-08-05 ファルマシア・コーポレーション ＨＳ−５ストロマ細胞系統由来のｃＤＮＡライブラリーから得られた新規Ｓｌｉｔ‐様蛋白質
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
US20050014680A1 (en) * 2003-04-15 2005-01-20 Crabtree Gerald R. Methods and compositions for enhancing neuron growth and survival
WO2005074556A2 (en) * 2004-01-30 2005-08-18 The General Hospital Corporation Netrin compositions and methods of use thereof
EP2104509A4 (en) * 2006-12-11 2010-03-24 Univ Utah Res Found COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL ANGIOGENESIS AND VASPERMEABILITY

Also Published As

Publication number Publication date
US20110002972A1 (en) 2011-01-06
CA2699411A1 (en) 2009-03-19
BRPI0816784A8 (pt) 2016-01-19
EP2212344A2 (en) 2010-08-04
BRPI0816784A2 (pt) 2015-03-24
AU2008297889A1 (en) 2009-03-19
WO2009033715A3 (en) 2010-03-18
RU2010114713A (ru) 2011-10-20
RU2496790C2 (ru) 2013-10-27
WO2009033715A2 (en) 2009-03-19
MX2010002716A (es) 2010-07-05
JP2010539123A (ja) 2010-12-16
ZA201001644B (en) 2011-03-30
KR20100075493A (ko) 2010-07-02
EP2212344B1 (en) 2014-03-26
CN101821283A (zh) 2010-09-01

Similar Documents

Publication Publication Date Title
EP2212344B1 (en) Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
Cucchiarini et al. Gene therapy for cartilage defects
KR100898765B1 (ko) 성장인자 복합체
EP1704866A2 (en) TGFbeta superfamily proteins for biological anchoring of connective tissue to bone
KR100688871B1 (ko) 연골세포 및 ＴＧＦ-β를 사용한 연골 재생
Song et al. Hyaline cartilage regeneration using mixed human chondrocytes and transforming growth factor-β1-producing chondrocytes
Madry et al. Clinical potential and challenges of using genetically modified cells for articular cartilage repair
US20250345393A1 (en) Isoform nell-1 peptide
US8691944B2 (en) Fibronectin polypeptides and methods of use
EP2036921A1 (en) Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
KR100702725B1 (ko) Ｔｇｆ-베타를 사용하는 유전자 요법
AU2003218464B2 (en) Bioadhesive directed somatic cell therapy
AU2006235200A1 (en) Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration
Aihaiti et al. The Role of Thrombospondins in Osteoarthritis: from Molecular Mechanisms to Therapeutic Potential
US20120208753A1 (en) Composition and Method for the Treatment or Prevention of Spinal Disorders III
WO2008028888A2 (en) Use of cripto-1 or cripto-3 for the treatment of skeletal muscle wasting
US11034753B2 (en) Regeneration and repair of mesenchymal tissue using amelogenin
AU2012216342A1 (en) Use of neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: FORMYCON GMBH, DE

Free format text: OLD OWNER(S): SCIL TECHNOLOGY GMBH

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO TITLE (54)

PSEA Patent sealed
ASS Change of ownership

Owner name: FORMYCON AG, DE

Free format text: OLD OWNER(S): FORMYCON GMBH

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 SEP 2015 BY AJ PARK

Effective date: 20130424

LAPS Patent lapsed